分化型甲状腺癌术后131I治疗发生第二原发恶性肿瘤的影响因素的研究进展

The Research Progress on Influencing Factors of Second Primary Malignancy in 131I Treatment of Differentiated Thyroid Cancer After Surgery

分化型甲状腺癌(differentiated thyroid cancer,DTC)是一种常见的内分泌恶性肿瘤,治疗方法包括:“甲状腺全切+131I治疗+TSH抑制治疗”,手术后联合131I及TSH抑制治疗可有效降低DTC的复发率及死亡率。但是,近年来关于131I治疗DTC后发生第二原发恶性肿瘤的报道逐渐增多,本文我们综述了目前关于DTC患者131I治疗后发生第二原发恶性肿瘤的影响因素,以期为临床工作提供一些帮助。

Differentiated thyroid cancer(DTC)is a common malignant tumor of the endocrine.The main treatment methods include:“thyroidectomy+131I treatment+TSH suppression therapy”.Combined with 131I and TSH suppression therapy after surgery can effectively reduce the recurrence of DTC,and the rate of mortality.In recent years,the occurrence of the second primary malignancy(SPM)after 131I treatment of DTC has gradually drawn attentions in the field.In this paper,we review the occurrence and influencing factors of SPM after 131I treatment of DTC,in order to provide some insights for the clinical work.